Google Platform Changes Spur Pharma Rethinking Of Search Engine Ads
Executive Summary
Widespread use of paid ads that display disease-specific website address differing significantly from destination hyperlink for branded product will end in January.
You may also be interested in...
Google Creates New Formats To Include Risk Information In Sponsored Search Results
Click-through rate on health condition search results declined dramatically since FDA citations, company says.
Internet Promotions Must Be Redesigned After FDA Cites Sponsored Web Links
Firms will need to redesign sponsored links that appear on Internet search engines or forgo using them at all, food and drug attorneys suggest following the agency's recent cluster of letters citing the promotions
Rare Diseases: CBER Looks To ‘Lean Into’ Accelerated Approval, Align More With CDER
US FDA biologics center officials spoke about their efforts to increase collaboration and harmonization with the drugs center, and to internally involve more review disciplines in evaluating biomarker evidence, during a Reagan-Udall Foundation meeting that weighed potential use of accelerated approval for neuronopathic mucopolysaccharidoses disorders.